Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics

NCT03288012 is registered in ClinicalTrials.gov with Sanquin Research & Blood Bank Divisions as lead sponsor.

NCT NCT03288012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03288012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics
Lead sponsor
Sanquin Research & Blood Bank Divisions
Phase
Observational
Overall status
Unknown status
Start date
September 20, 2017
Completion date
December 31, 2021
Enrollment
150 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

alloimmunization, sickle cell disease